H. Lundbeck A/S Completes Acquisition Of Chelsea Therapeutics, Inc.

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

DEERFIELD, Ill.--(BUSINESS WIRE)--H. Lundbeck A/S (Lundbeck) today announced that it has completed its acquisition of Chelsea Therapeutics International, Ltd. (NASDAQ: CHTP) (Chelsea) for USD 6.44 per share in cash and non-transferable contingent value rights that may pay up to an additional USD 1.50 per share upon achievement of certain sales milestones, in each case without interest and subject to any required withholding of taxes. As a result of the acquisition, Chelsea became a wholly-owned indirect subsidiary of Lundbeck, and shares of Chelsea common stock will no longer be listed on the NASDAQ Capital Market.

Help employers find you! Check out all the jobs and post your resume.

Back to news